Research Spotlight

Posted September 20th 2020

Priscilla F. Butler, MS – Pioneer in radiation dose assessment and image quality.

Debra L. Monticciolo. M.D.

Debra L. Monticciolo. M.D.

Monticciolo, D.L. (2020). “Priscilla F. Butler, MS – Pioneer in radiation dose assessment and image quality.” Clin Imaging Aug 22;S0899-7071(20)30310-7. [Epub ahead of print.].

Full text of this article.

Few people have had the impact that Priscilla “Penny” Butler, MS, has had on radiological technique in the United States. Being a woman leader in medical physics is equally rare. Penny forged both new avenues for women and new ideas for all during her long and productive career in the radiological sciences. She has done so with such grace and humility as to always remain accessible to those with whom she worked and served. This year, Ms. Butler was awarded the American College of Radiology Gold Medal, the College’s highest honor. She is only the 10th woman to receive this recognition, the first being Madame Marie Curie in 1931. In this editorial, we celebrate Ms. Butler for her ground breaking roles in radiological dose assessment and image quality. [No abstract; excerpt from Editorial.].


Posted September 20th 2020

Sarecycline: A Review of Preclinical and Clinical Evidence.

Angela Y. Moore M.D.

Angela Y. Moore M.D.

Moore, A.Y., Del Rosso, J., Johnson, J.L. and Grada, A. (2020). “Sarecycline: A Review of Preclinical and Clinical Evidence.” Clin Cosmet Investig Dermatol 13: 553-560.

Full text of this article.

Sarecycline is a tetracycline-derived oral antibiotic, specifically designed for acne, and is approved by the Food and Drug Administration (FDA) in 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris (AV) in patients 9 years of age and older. It has been decades since a novel systemic antibiotic was approved to treat AV, a disease that affects up to 90% of teenagers and young adults worldwide and lasts well into adulthood. Sarecycline holds promise to yield fewer side effects than other commonly used broad-spectrum tetracyclines, including minocycline and doxycycline. The narrower spectrum of antibacterial activity of sarecycline, which specifically targets C. acnes and some Gram-positive bacteria with little or no activity against Gram-negative bacteria, suggests not only the potential for reduced emergence of antibiotic-resistant bacterial strains but also less disruption of the human gut microflora. Here, we review the key preclinical and clinical evidence on sarecycline.


Posted September 20th 2020

An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.

Andrew Minzenmayer, M.D.

Andrew Minzenmayer, M.D.

Minzenmayer, A.N., Miranda, R.N., Powell, P.R. and Parekh, P.K. (2020). “An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.” J Cutan Pathol 47(9): 850-853.

Full text of this article.

Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma with bone marrow involvement and a monoclonal IgM gammopathy. Infiltration of the skin by neoplastic cells is very rare, and it can be difficult to distinguish from marginal zone lymphoma. The MYD88 L265P mutation is strongly associated with Waldenström macroglobulinemia, and it may be helpful in differentiating the two disorders, although the presence of this mutation is not specific, and other factors must be considered when making the final diagnosis. We present a diagnostically challenging case of cutaneous Waldenström macroglobulinemia in which the MYD88 L265P mutation was identified in the skin but not in the bone marrow, due to a low tumor burden.


Posted September 20th 2020

Preemptive analgesia in hip arthroscopy: intra-articular bupivacaine does not improve pain control after preoperative peri-acetabular blockade.

Hal D. Martin, D.O.

Hal D. Martin, D.O.

Kazum, E., Rath, E., Shlaifer, A., Sharfman, Z.T., Martin, H.D., Eizenberg, G., Reider, E. and Amar, E. (2020). “Preemptive analgesia in hip arthroscopy: intra-articular bupivacaine does not improve pain control after preoperative peri-acetabular blockade.” Hip Int Aug 31;1120700020950247. [Epub ahead of print.]. 1120700020950247.

Full text of this article.

INTRODUCTION: Literature addressing postoperative pain management after hip arthroscopy is relatively scarce. This study aimed to assess if there was added analgesic benefit associated with postoperative intra-articular bupivacaine blockade for patients who received preoperative peri-acetabular blockade for hip arthroscopy procedures. METHODS: 52 patients were included in this comparative cohort study. Group 1 consisted of 20 patients who received preoperative peri-acetabular blockade and postoperative intra-articular blockade. The control group (Group 2), consisted of 32 patients who received only preoperative peri-acetabular blockade. Postoperative pain was recorded via visual analogue scale (VAS) pain scores, analgesic consumption, and pain diaries for 2 weeks postoperatively. RESULTS: Postoperative VAS pain scores were significantly lower in the experimental group at the 30-minute recovery room assessment (VAS scores Group 1: 1.1; Group 2: 3.00, p = 0.034). Other than the 30-minute recovery room assessment, VAS pain scores, narcotic medication consumption, and non-narcotic analgesic consumption did not differ between the 2 groups at any time point in the study period. CONCLUSIONS: This study did not demonstrate significant clinical benefit for patients who receive postoperative intra-articular blockade in addition to preoperative peri-acetabular blockade with bupivacaine 0.5%. We recommend the use of preoperative peri-acetabular bupivacaine blockade without intra-articular blockade postoperatively for pain control in the setting of hip arthroscopy surgery.


Posted September 20th 2020

Expanding the clinical and genetic spectrum of PCYT2-related disorders.

Colleen Macmurdo, M.D.

Colleen Macmurdo, M.D.

Vélez-Santamaría, V., Verdura, E., Macmurdo, C., Planas-Serra, L., Schlüter, A., Casas, J., Martínez, J.J., Casasnovas, C., Si, Y., Thompson, S.S., Maroofian, R. and Pujol, A. (2020). “Expanding the clinical and genetic spectrum of PCYT2-related disorders.” Brain Aug 21;awaa229. [Epub ahead of print.].

Full text of this article.

Recently, Vaz et al. reported four families with complex hereditary spastic paraplegia (cHSP) and biallelic variants in PCYT2 encoding CTP: phosphoethanolamine cytidylyltransferase (ET), the rate-limiting enzyme for phosphatidylethanolamine biosynthesis. Patient-derived fibroblasts and plasma had significant abnormalities in both neutral etherlipid and etherphospholipid metabolism (Vaz et al., 2019). We wish to broaden the phenotypic and genetic spectrum of PCYT2-related disorders with two additional patients. [No abstract; excerpt from article.].